Chiesi Global Rare Diseases committed up to $115 million in a collaboration with CRISPR startup Arbor Biotechnologies to develop an in vivo gene‑editing therapy for primary hyperoxaluria type 1, marking Chiesi’s first major push into genetic medicines. The deal positions Chiesi to advance an in‑liver editing program and expand its rare disease portfolio. Separately, a study presented in Seville reported that some patients with anti‑AAV antibodies could still be candidates for gene therapy, challenging exclusion criteria based purely on serostatus. Together, the transaction and the antibody data suggest both commercial and scientific moves to expand in‑vivo genetic medicine access for inherited liver disorders.